A Study of Allopurinol to Relieve Symptoms in Patients with Heart Failure and High Uric Acid Levels


About this study

The purpose of this study is to determine if allopurinol is effective in relieving symptoms for patients who have heart failure and high blood uric acid levels.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • NYHA class II-IV heart failure due to ischemic or non-ischemic cardiomyopathy
  • Left ventricular ejection fraction ≤ 40% by echocardiography
  • Heart failure symptoms for 3 months despite standard treatment
  • Serum uric acid level ≥ 9.5 mg/dl
  • At least one of the following additional markers of increased risk
    • Hospitalization
    • ER visit or urgent clinic visit for heart failure requiring IV diuretics within the previous 12 months
    • Left ventricular ejection fraction ≤ 25
    • B-type natriuretic peptide level > 250 pg/ml

Exclusion Criteria

  • Hypertrophic or restrictive cardiomyopathy, constrictive pericarditis, biopsy-proven myocarditis, severe stenotic valvular disease, or complex congenital heart disease
  • Acute coronary syndrome, PCI or CABG within 3 months
  • Current ventricular assist device or ventricular assist device or heart transplant likely within the next 6 months
  • Uncontrolled hypertension (i.e., SBP > 170 mm Hg or DBP > 110 mm Hg)
  • Serum creatinine > 3 mg/dL or estimated GFR < 20 ml/min
  • Evidence of active hepatitis with ALT and AST greater than 3x normal
  • Any condition other than HF which could limit the ability to perform a 6-minute walk test
  • Any diseases other than HF which are likely to alter the patient's global perception of status or quality of life over a period of 6 months
  • Receiving treatment with allopurinol currently or within 30 days, or having symptomatic hyperuricemia which requires treatment with allopurinol

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Margaret Redfield, M.D.

Closed for enrollment

Albert Lea, Minn.

Mayo Clinic principal investigator

Margaret Redfield, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer